Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 124 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: levodopa/carbidopa Clear all
Completed Phase 4 Interventional Results available

Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study

NCT00590122
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Parcopa, carbidopa-levodopa (Sinemet)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
31 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 2, 2026, 7:41 PM EDT
Completed No phase listed Observational

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

NCT02611713
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Levodopa for the Treatment of Residual Amblyopia

NCT01190813
View directory record Official record
Conditions
Amblyopia
Interventions
Levodopa/Carbidopa, Placebo, Patching
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

NCT00335153
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Levodopa for Diabetic Retinopathy

NCT07444892
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

NCT00955045
View directory record Official record
Conditions
Parkinson's Disease
Interventions
istradefylline
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Measuring Parkinson's Disease Progression

NCT03205956
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa
Drug
Lead sponsor
Kevin J. Black, MD
Other
Eligibility
40 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

NCT00203164
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

NCT00253084
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX054 200 mg, CD-LD IR, IPX054 Placebo, CD-LD IR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 2, 2026, 7:41 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Improving Therapeutic Learning for PTSD

NCT04558112
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder
Interventions
L-DOPA, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Austin, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Results available

Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

NCT00829439
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Levodopa/Carbidopa (4:1)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

NCT00099268
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

NCT05094050
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 2, 2026, 7:41 PM EDT
Suspended Phase 2Phase 3 Interventional

Effects of 5HTP and LDOPA on CNS Excitability After SCI

NCT04000919
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
5HTP, L-DOPA, Placebo oral tablet, Carbidopa
Drug
Lead sponsor
Jessica M D'Amico
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

NCT02549092
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Augmenting Language Therapy for Aphasia: Levodopa

NCT01429077
View directory record Official record
Conditions
Nonfluent Aphasia, Stroke
Interventions
levodopa/carbidopa, Placebo comparator
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 25, 2013 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

NCT03007888
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Sinemet, IPX203
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Naples, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm

NCT06587217
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
View directory record Official record
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 2, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

NCT00203177
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, rasagiline mesylate 1.0 mg
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 2, 2026, 7:41 PM EDT